Skip to main
ELMD
ELMD logo

Electromed (ELMD) Stock Forecast & Price Target

Electromed (ELMD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Electromed Inc. has demonstrated significant financial growth, with homecare revenue increasing by 14.8% to $14.1 million, attributed to enhanced sales rep productivity and effective demand generation initiatives. The company has successfully expanded its presence in the domestic homecare market while also making strides in acute care and select international markets, as indicated by a remarkable rise in distributor sales by 41% and hospital sales by 52%. Although SG&A expenses rose by 17.2% due to investments in sales, marketing, and reimbursement, these expenditures reflect a strategic commitment to support ongoing growth and capitalize on market opportunities.

Bears say

Electromed Inc faces a negative outlook primarily due to margin compression, competitive headwinds, and decreased productivity among sales representatives, which collectively hinder its ability to achieve growth targets. Additionally, delays in the expansion of its Pain Management and Wound Care segments are expected to adversely affect anticipated growth rates and overall profit margins. The decline in share prices from a peak of $35.43 to around $18 further underscores investor concerns regarding the company’s financial stability and market position.

Electromed (ELMD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Electromed (ELMD) Forecast

Analysts have given Electromed (ELMD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Electromed (ELMD) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Electromed (ELMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.